Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    75.0%

    Based on 3 completed trials

    Completion Rate
    75%(3/4)
    Active Trials
    0(0%)
    Results Posted
    33%(1 trials)
    Terminated
    1(20%)

    Phase Distribution

    Early Phase 1
    1
    20%
    Phase 1
    1
    20%
    Phase 2
    2
    40%

    Phase Distribution

    2

    Early Stage

    2

    Mid Stage

    0

    Late Stage

    Phase Distribution4 total trials
    Early Phase 1First-in-human
    1(25.0%)
    Phase 1Safety & dosage
    1(25.0%)
    Phase 2Efficacy & side effects
    2(50.0%)

    Highest Phase Reached

    Phase 2

    Trial Status & Enrollment

    Completion Rate

    75.0%

    3 of 4 finished

    Non-Completion Rate

    25.0%

    1 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    5

    all time

    Status Distribution
    Completed(3)
    Terminated(1)
    Other(1)

    Detailed Status

    Completed3
    unknown1
    Terminated1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    5
    Active
    0
    Success Rate
    75.0%
    Most Advanced
    Phase 2

    Trials by Phase

    Early Phase 11 (25.0%)
    Phase 11 (25.0%)
    Phase 22 (50.0%)

    Trials by Status

    unknown120%
    completed360%
    terminated120%

    Recent Activity

    0 active trials
    Showing 5 of 5
    completedphase_2

    Thrombosomes® in Acute Thoracic Aortic Dissections

    NCT05771831
    unknown

    Thrombosomes for Expanded Access Use

    NCT04619108
    terminatedphase_2

    Thrombosomes® in Bleeding Thrombocytopenic Patients Study

    NCT04631211
    completedphase_1

    Thrombosomes® in Bleeding Thrombocytopenic Patients

    NCT03394755
    completedearly_phase_1

    Evaluation of the Safety and Immunogenicity of Autologous Thrombosomes® in Healthy Human Subjects; A Microdose Escalation Study (Cohorts 1 - 4) and Repeat Microdose Immunogenicity Study (Cohort 5)

    NCT02223117

    Clinical Trials (5)

    Showing 5 of 5 trials
    NCT05771831Phase 2

    Thrombosomes® in Acute Thoracic Aortic Dissections

    Completed
    NCT04619108

    Thrombosomes for Expanded Access Use

    Unknown
    NCT04631211Phase 2

    Thrombosomes® in Bleeding Thrombocytopenic Patients Study

    Terminated
    NCT03394755Phase 1

    Thrombosomes® in Bleeding Thrombocytopenic Patients

    Completed
    NCT02223117Early Phase 1

    Evaluation of the Safety and Immunogenicity of Autologous Thrombosomes® in Healthy Human Subjects; A Microdose Escalation Study (Cohorts 1 - 4) and Repeat Microdose Immunogenicity Study (Cohort 5)

    Completed

    All 5 trials loaded

    Drug Details

    Intervention Type
    Biological
    Total Trials
    5